Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy

NCT00866320 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT00866320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00866320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
December 31, 2009
Enrollment
49 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer